The absorption enhancing eŠect of 1-[2-(decylthio) ethyl] azacyclopentan-2-one (Pirotiodecane), on drug permeation across rabbit nasal mucosa was studied. The nasal epithelial mucosa was isolated from rabbit nasal septum and mounted in an Ussing chamber to allow for monitoring of the membrane resistance (Rm), and the permeation of ‰uorescein isothiocyanate-labeled dextran (FD-4, M.W. 4,400 Da). Treatment with 0.05, 0.1, and 0.2z Pirotiodecane for 60 min decreased Rm, and increased the cumulative amount of FD-4 permeated in a concentration-dependent manner, suggesting that Pirotiodecane possesses passively a disassembly of tight junction to enable the enhanced FD-4 permeation. The remarkable increase in plasma concentration of FD-4 was also observed in intranasal co-administration with 1z Pirotiodecane in rabbits. The Rm was virtually maintained after the removal of Pirotiodecane, although recovery of Rm was not seen. On the other hand, the increase in plasma concentration of FD-4 with intranasal co-administration of 1z Pirotiodecane in rabbits in vivo was not observed in FD-4 administration at 15-60 min after administration of 1z Pirotiodecane alone. It was concluded that Pirotiodecane possesses a relatively short absorption enhancing eŠect through nasal epithelial.
Introduction
Drugs are selectively transported across epithelial and endothelial cellular sheets, and this occurs either by mainly transcellular transport through the cell or by paracellular ‰ux through tight junctions (TJs). TJs are responsible for preventing the diŠusion of solutes through the intercellular space between adjacent cells, but not simply impermeable barriers, hence allowing the transport of some solutes including drugs. 1) Nasal administration has the advantage of providing direct entry of a drug into the systemic circulation through the extensive capillary networks without thê rst pass metabolisms in the liver. 2) Furthermore, the nasal route is often selected as a dosing route of a peptide drug for systemic application, because the nasal cavity has the following advantages that proteolytical activity is poor 3, 4) and the structural barrier is leakier 5, 6) than that in the gastrointestinal tract. However, in a case of peptide or protein-like compounds whose molecular weights are 1,000 Da or higher, the bioavailability is reduced to 0.5-5z. 7, 8) As one of the strategies to improve bioavailability, it has been noted that the membrane permeability is improved by absorption enhancers such as bile acids, [9] [10] [11] [12] fatty acids, 12) surfactants 13, 14) and chelating agents. 12) Pirotiodecane is an absorption enhancer developed by focusing on cysteine, which is a keratin-constituting amino acid of the cuticle as well as a pyrrolidone derivative that is a moisturizing component in the skin.
Previous reports suggested that Pirotiodecane has an enhancing eŠect on percutaneous absorption of a large number of drugs such as 5-‰uorouracil and indomethacin. 15) Abe et al. reported that the combined use of Pirotiodecane and 2-hydroxypropyl-b-cyclodextrin improved the nasal absorption of insulin 16) (36,000 Da as a hexamer) or buserelin 17) (1,239 Da) without any adverse eŠect on the nasal mucosa. In their studies, the mechanism of action remains unknown, although it is shown that Pirotiodecane alone possesses the enhancing eŠect on the nasal absorption of these compounds described above.
In the present study, we examined the relationship between membrane permeation of ‰uorescein isothiocyanate-labeled dextran (FD-4, M.W. 4,400 Da) and changes in membrane resistance of rabbit nasal mucosa induced by Pirotiodecane based on in vitro electrophysiological analysis. We also examined the enhancing eŠect of Pirotiodecane on nasal absorption of FD-4 in the rabbit.
Materials and Methods
Materials: Pirotiodecane was gifted from Hisamitsu Pharmaceutical Co., Inc., Japan. FD-4 and urethane were purchased from Sigma-Aldrich, USA. Polyoxyethylene hydrogenated castor oil 60 (HCO-60 } ) was purchased from Nikko Chemicals Co., Ltd., Japan. Sodium pentobarbital solution (Nembutal } ) was purchased from Dainippon Pharmaceutical Co. Ltd., Japan. All other reagents were of analytical grade or better.
Preparation of isolated nasal mucosa: Nasal mucosa was isolated from male Japanese white rabbits (Japan Laboratory Animals, Inc., Tokyo, Japan), according to the methods previously described by Hosoya et al.
6) The rabbits weighing 2.5-3.0 kg, were fasted overnight and sacriˆced by a lethal injection of Nembutal } in order to avoid pain to animals. All animal experiments complied with the standards set out in the guidelines of Tokyo University of Science. The nasal septum was gently isolated and put into ice-cold Krebs-Henseleit bicarbonate buŠer (KHBB; pH 7.4) containing the following compounds at the indicated concentrations (in mmol W L): NaCl, 136.9; KCl, 5.4; Na2HPO4, 0.3; KH2PO4, 0.4; MgSO4:7H2O, 0.4; glucose, 19.5; MgCl2:6H2O, 0.5; NaHCO 3 , 4.2; CaCl 2 :2H 2 O, 1.3; and HEPES, 10. Two nasal mucosae were carefully peeled from the nasal septum and mounted as a ‰at sheet in Ussing chambers with an exposed area of 0.67 cm 2 . The mucosal and serosal sides of the chamber were immediatelyˆlled with 5 mL of KHBB and then continuously bubbled with 95zO2-5zCO2 gas. The chambers were maintained at 379 C. Measurement of electrical membrane resistance and mucosal permeability of FD-4: The membrane potential diŠerence (PD) was measured using Ag-AgCl electrodes placed close to the surface of the two sides of the membrane. The electrodes were connected to a short circuit current ampliˆer (CEZ-9100, JEOL, Tokyo, Japan). For measurements of the short circuit current (Isc), the membrane potential diŠerence (PD) was maintained at 0 mV by voltage clamp. Membrane Resistance (Rm) was calculated using Ohm's law by applying a 1-mV pulse (1 sec×2) and measuring current de‰ection. Fluid resistance was subtracted and net resistance expressed as Q･cm 2 . After the preincubation period for 60-90 min, the nasal membrane was relatively stable and ready to use. The PD of 4.7±1.4 mV, Isc of 107.6±30.1 mA W cm 2 , and Rm of 43.6± 1.3 Q･cm 2 were observed for stabilized nasal membrane (mean±S.E.).
After the nasal mucosa was mounted on the chamber and incubated for 90 min, the KHBB of the mucosal side compartment was replaced with 0.5z FD-4 with or without Pirotiodecane. 0.5z FD-4 did not aŠect electrophysiological parameters. Thereafter, every 10 min, 200 mL-sample of buŠer was obtained from the serosal side compartment, and every time the same volume of fresh HCO-60 } W KHBB was added to make up the portion used. The measurement of FD-4 concentrations was performed with a plate leader ‰uorescent photometer (PerSeptive Biosystems, Series 400, MA, USA), at an excitation wavelength of 490 nm and an emission wavelength of 520 nm.
EŠects of Pirotiodecane in vitro:
The enhancing eŠects of Pirotiodecane on permeation of FD-4 were expressed as a cumulative amount of FD-4 permeated per membrane area ( mg W cm 2 ) for 60 min after the addition of Pirotiodecane. An area under the curve of the cumulative amount of FD-4 was calculated from time-course proˆle. The cumulative amount of FD-4 at 60 min after the addition of Pirotiodecane was subtracted a cumulative amount in the absence of Pirotiodecane from that in the presence of Pirotiodecane. Apparent permeation coe‹cient (Papp) was calculated as follows:
dQ W dt is the transport rate (steady state(from 40 to 60 min) transport rate, mg W sec) and corresponds to the slope of the regression line, C0 is the initial concentration in the donor chamber ( mg W mL), and A is the membrane area. The membrane area was calculated from the exposed area of the Ussing chamber (0.67 cm 2 ). The changes in Rm when treated with Pirotiodecane were expressed as the diŠerence ( DRm) from the Rm value just before the addition of Pirotiodecane (at 90 min). Furthermore, an area under the ratios of DRmtime curve (Rm-AUC) was calculated as follows:
The DRm AUC90-150 was the calculated area under the DRm curve from 90 min to 150 min. Atˆrst, for investigation of in vitro reversibility, the preincubation period with KHBB was 90 min after removing the nasal mucosa from the rabbits. But recovery of the reduction in Rm with Pirotiodecane was not conˆrmed after the removal of Pirotiodecane. It was considered to be one of the causes that the longtime aqueous condition in vitro was severe for the nasal mucosa usually exposed to the air. Hence, the preincubation period with KHBB was shortened to 60 min, according to the methods described by Bechgaard et al., 18) in order to keep the mucosal damage to a minimum. At the 60 min when the electrophysiological parameters became stabilized, the KHBB of the mucosal side compartment was replaced with Pirotiodecane solution and the electrophysiological parameters were measured. After the treatment with Pirotiodecane for 60 min, the compartments were washed with KHBB twice gently, followed by addition of KHBB to the mucosal side and the serosal side. Then the electrophysiological parameters were measured continuously for 60 min.
EŠects of Pirotiodecane in vivo: The concentrations of Pirotiodecane and FD-4 solutions were used at 1z and 1 mg W kg, respectively. The concentration of Pirotiodecane was reported to promote the nasal absorption of insulin 16) or buserelin, without tissue damage.
17) The methods of administration of Pirotiodecane and FD-4 solutions were according to the method of Vermehren et al. 19) Male Japanese white rabbits (Japan Laboratory Animals, Inc., Tokyo, Japan), weighing 2.5-3.0 kg, were used without anesthesia through the nose. All animal experiments complied with the standards set out in the guidelines of Tokyo University of Science. Pirotiodecane and FD-4 were administered at the same time or FD-4 was administered at 15, 30, or 60 min after the administration of Pirotiodecane. The dosing volume wasˆxed to 75 mL W nostril, which was reported to induce no irritation to the nasal mucosa. 20) About 500 mL of the heparinized blood was collected from the auricle vein at 2, 5, 10, 15, 20, 30, 45 and 60 min after the administration of FD-4. After the blood samples were centrifuged, plasma was diluted 5-fold with KHBB. The plasma concentrations of FD-4 were determined by a ‰uorescent spectrophotometer (JASCO, FP6500, Tokyo, Japan), at an excitation wavelength of 492 nm and an emission wavelength of 515 nm (Lower limit of quantiˆcation: 6.1 ng W mL). After all the procedures had been completed, the animals were sacriˆced by a lethal injection of Nembutal } .
Statistical method: All results are expressed as mean ±SEM and statistically analyzed by Bartlett's test for homoscedasticity, followed by Williams', Shirley's or Dunnett's multiple test. Pº0.05 was deˆned as statistically signiˆcant.
Results

EŠects of Pirotiodecane on membrane resistance (Rm) and membrane permeability of FD-4
Changes in the Rm of nasal mucosa when treated with 0.01 to 0.2z Pirotiodecane were shown in terms of the DRm (Fig. 1) . Under the treatment of 0.01 and 0.025z Pirotiodecane conditions, no marked change was observed when compared with control conditions (0.6z HC HCO-60 } W KHBB), but treatment with 0.05, 0.1, and 0.2z Pirotiodecane remarkably decreased Rm. In particular, in treatment with 0.2z Pirotiodecane, Rm The cumulative amount of FD-4 was expressed as an AUC calculated from time-course proˆle. The Rm-AUCs were calculated from the DRm curve of 0.01 to 0.2z Pirotiodecane treatments. The ratios of the Rm-AUC changed by the Pirotiodecane treatment to the Rm-AUC in the control and the cumulative amount of FD-4 permeated per membrane area at 60 min were in a concentration-dependent manner ( Fig. 2A) . Moreover, when the cumulative amount was compared with the Rm-AUCs for 60 min ( Fig. 2A and Fig. 2B ), a good correlation was obtained (R 2 ＝0.80, pº0.05).
In vitro reversibility: Figure 3 shows the reversibility of TJ that had been widened by Pirotiodecane. When the membranes were treated with 0.05, 0.1, and 0.2z Pirotiodecane for 60 min, Rm decreased in a concentration-dependent manner. Recovery of Rm was not seen in spite of removal of Pirotiodecane, but Rm was virtually maintained after Pirotiodecane was removed.
EŠects of Pirotiodecane in vivo: The eŠects of Pirotiodecane in vivo are shown in Fig. 4 . Nasal administration of 1 mg W kg FD-4 immediately after nasal administration of 1z Pirotiodecane resulted in a signiˆcant increase in the plasma concentration of FD-4 compared to administration of FD-4 alone (control conditions). When Pirotiodecane and FD-4 were simultaneously administered, the area under the plasma FD-4 concentration curve (AUC) of FD-4 was 88.0± 3.46 mg･min W mL. The AUC was about 6-fold as high as those in the control condition (14.4±1.58 mg･min W mL). When FD-4 was administered at 15, 30 and 60 min after administration of Pirotiodecane, the AUC of FD-4 in such groups (21.5±4.04, 19.8±6.52 and 23.3±2.48 mg ･min W mL, respectively) was similar to that of the control conditions.
Discussion
In the present study, using the nasal mucosa of rabbits in vitro, we examined the relationships between structural changes of nasal membrane based on electrophysiological analysis and with permeation changes of FD-4 with Pirotiodecane. Treatment with 0.01 to 0.2z Pirotiodecane decreased Rm of rabbit nasal mucosa in a concentration-dependent manner (Fig. 1) .
Furthermore, Pirotiodecane enhanced the cumulative amount of FD-4 permeated in a concentration-dependent manner (Fig. 2A) . Moreover, the cumulative amount was correlated well with ratios of the Rm-AUCs by the Pirotiodecane treatment to the Rm-AUC in control condition (Fig. 2B, R 2 ＝0.80, pº0.05). Tomita et al. demonstrates that a speciˆc transporter for hydrophilic probes such as FD-4 exists in the colon and has probably played a role in excretion. 21) There is a possibility that a speciˆc transporter similar to the speciˆc transporter exists in the nasal mucosa of rabbits. Hosoya et al. indicated that ‰uxes of FD-4 at the concentration of 0.5z from the mucosal side and the serosal side were equal in the nasal mucosa by the Ussing Chamber system. 6) Hence, it was considered that if a special transportation system exists in a nasal membrane, it might be saturated in the concentration of FD-4. When the FD-4 concentration was 0.5z or more, the penetration pathway(s) other than the paracellular route is also suggested to be negligible. Nakamura et al. has reported that a permeation of FD-4 correlates to AUC of trans-epithelial electrical resistance (TEER) in nasal membrane treated with sodium caprate 22) and b-sitosterol, which promotes absorption of FD-4 by paracellular ‰ux through tight junctions and b-sitosterol b-D-glucoside, which promotes by mainly transcellular transport through the cell, and does not aŠect nasal membrane TEER. 23) Therefore, in the present study, it was suggested that the cumulative amount of FD-4 permeated could be regarded as the cumulative amount of the paracellular route.
1z Pirotiodecane signiˆcantly enhanced the absorption of FD-4 administered immediately after the administration of Pirotiodecane, but the result for FD-4 administered 15 to 60 min after Pirotiodecane administration was not diŠerent from control (Fig. 4) . Since a marked absorption enhancing eŠect was observed in a relatively short period of several minutes in vivo, we can expect its eŠectiveness as an absorption enhancer.
Bagger et al. reported that when 1z sodium glycocholate was administered simultaneously with peptide T to rabbits via the nasal route, AUC of peptide T increased to about 7-fold that of the control conditions. 20) On the other hand, in our study, AUC of FD-4 was increased to about 6-fold that of the control conditions when Pirotiodecane and FD-4 were simultaneously administered (88.0 mg･min W mL vs. 14.4 mg･ min W mL in the control condition). Considering that the molecular weight of FD-4 (MW: 4,400) is higher than that of peptide T (MW: 857), Pirotiodecane has an absorption enhancing eŠect on a higher molecular compound than sodium glycocholate. 20) Pirotiodecane seems to possess a potential in the enhancement of nasal absorption, hence expecting intranasal application to high molecular weight peptides or proteins in delivery.
Complete recovery of the reduction in Rm of the rabbit nasal mucosae mounted on an Ussing Chamber with Pirotiodecane was not conˆrmed after the removal of Pirotiodecane, but Rm at the time when Pirotiodecane was removed was mostly maintained (Fig. 3) . As the reason why that complete recovery was not observed in vitro, the following factor can be considered. Pirotiodecane is poorly soluble in water and extremely di‹cult to dissolve in water. Since both mucosal and serosal sites were in contact with aqueous solvents, Pirotiodecane was thought to tend to remain in the tissue even after it was washed out. Pirotiodecane may su‹ciently exert its eŠect in the tissue even at a low concentration, and it takes much time to restore the membrane to control condition. Perhaps there is a possibility that the nasal mucosae exposed to Pirotiodecane for a long time may have extracted membrane constituent. 24) In order to clarify these points, further studies are required in the future.
In conclusion, Pirotiodecane remarkably enhanced the nasal absorption of FD-4 in vitro and in vivo, although complete recovery of membrane resistance after removal of Pirotiodecane was di‹cult to observe. Pirotiodecane seems to possess a potential for absorption enhancement of nasally administered peptides and proteins, even though further studies remain to clarify its safety and mechanism.
